Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.970
+0.010 (0.34%)
Mar 3, 2026, 4:00 PM EST - Market closed
Adagene Employees
Adagene had 138 employees as of December 31, 2024. The number of employees decreased by 36 or -20.69% compared to the previous year.
Employees
138
Change (1Y)
-36
Growth (1Y)
-20.69%
Revenue / Employee
$748
Profits / Employee
-$216,592
Market Cap
139.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
| Sep 30, 2020 | 199 | - | - |
| Jun 30, 2020 | 172 | - | - |
Related Stocks
Employee RankingsADAG News
- 14 days ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Adagene Provides Business Update and 2026 Objectives - GlobeNewsWire
- 2 months ago - Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewsWire
- 3 months ago - Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
- 4 months ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 6 months ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 6 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 6 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire